Yes, malignant tumors can spread to other parts of the body, and this ability is what makes them malignant. The process is called metastasis, and it’s the primary reason cancer becomes life-threatening. Not every malignant tumor will spread, but all of them have the biological machinery to do so. Benign tumors, by contrast, grow in place and don’t invade surrounding tissue or travel to distant organs.
How Cancer Cells Leave the Original Tumor
Spreading isn’t a single event. It’s a chain of steps, each of which a cancer cell must survive to form a new tumor somewhere else. First, some cells lose the molecular “glue” that holds them to neighboring cells in the original tumor. Once detached, they begin breaking down the surrounding tissue, essentially digesting the structural scaffolding that normally keeps cells in place. This allows them to push into nearby tissue, a step called invasion.
Next, these migrating cells need to reach the bloodstream or lymphatic system. They do this by penetrating the walls of small blood vessels or lymphatic channels near the tumor. Once inside, they’re carried throughout the body. This journey is hostile: the cells face mechanical shear from blood flow, attacks from immune cells, and a generally inhospitable environment. The vast majority of circulating tumor cells die. But the few that survive eventually lodge in the small vessels of a distant organ, push through the vessel wall into the surrounding tissue, and begin growing into a new tumor.
The Routes Cancer Uses to Travel
Cancer cells reach distant sites through two main highways: the bloodstream and the lymphatic system. Lymphatic vessels are a network of thin channels that drain fluid from tissues and pass through lymph nodes, which is why swollen lymph nodes near a tumor are often the first sign of spread. Importantly, lymphatic vessels eventually drain into large veins, so cells that enter the lymphatic system can still end up in the blood circulation and reach organs far from the original tumor.
Which route a tumor favors depends on the cancer type and the biology of the tumor itself. Some tumors readily invade blood vessel walls and enter the bloodstream directly. Others, less equipped to cross blood vessel barriers, may default to nearby lymphatic channels as an easier exit route. Either way, both paths can ultimately deliver cancer cells to distant organs.
Where Different Cancers Tend to Spread
Metastasis isn’t random. Different cancers show strong preferences for specific organs, a pattern researchers call organotropism. Breast cancer, for example, most commonly spreads to bone, lung, liver, and brain. Prostate cancer has a particularly strong tendency to metastasize to bone. Cancers that originate in the digestive tract, including stomach, pancreatic, and colorectal cancers, frequently establish their first distant metastases in the liver before spreading further to places like the lungs.
These patterns exist partly because of blood flow (the liver, for instance, filters blood from the intestines, so colorectal cancer cells get trapped there) and partly because tumors actively prepare certain organs in advance. Primary tumors release tiny particles called extracellular vesicles into the bloodstream. These vesicles travel to distant organs and trigger changes that make the tissue more hospitable: blood vessels become leakier, the structural framework of the tissue gets remodeled, immune defenses are suppressed, and new blood vessel growth is stimulated. By the time a circulating cancer cell arrives, the organ has already been primed to support its survival. Researchers call this a “pre-metastatic niche.”
How Doctors Determine If a Tumor Has Spread
Cancer staging uses a system called TNM, where T describes the size of the original tumor, N indicates whether nearby lymph nodes are involved, and M tells whether the cancer has spread to distant sites. A tumor classified as M0 has no detectable distant spread. M1 means distant metastasis is present. Any cancer that reaches stage IV has metastasized, regardless of the original tumor’s size or lymph node involvement. In some cancers, like colorectal, the M category is further refined: M1a means spread to one distant area, M1b to two or more areas, and M1c means spread to the lining of the abdominal cavity.
The standard workup for detecting spread typically starts with CT scans of the chest and abdomen. For more detailed evaluation, doctors may use PET/CT, which highlights areas of abnormally high metabolic activity and can catch metastases that don’t yet show obvious structural changes on a regular CT. MRI has the highest accuracy for detecting spread to the spine and is recommended when spinal metastases are suspected. Bone scans are still used for certain cancers, particularly breast cancer, to screen for skeletal involvement.
A newer approach called liquid biopsy can detect fragments of tumor DNA or actual circulating tumor cells in a simple blood draw. This technique is particularly valuable for catching metastasis early, before tumors are large enough to appear on imaging, and for monitoring whether treatment is working in real time.
How Spread Changes Survival Outlook
The difference between localized and metastatic cancer is stark. When lung cancer has spread to distant organs, the five-year survival rate drops to about 9%. For metastatic breast cancer, the five-year survival rate is around 30% for women and 19% for men. These numbers reflect how much harder it is to treat cancer once it has established itself in multiple locations throughout the body.
That said, survival statistics represent averages across large populations. Individual outcomes vary widely depending on where the cancer has spread, how many sites are involved, how the cancer responds to treatment, and the person’s overall health.
How Treatment Changes Once Cancer Spreads
When a tumor is localized, the goal of treatment is typically a cure. Surgery removes the tumor, and radiation may target the area to destroy any remaining cells. The focus is local: eliminate the cancer where it lives.
Once cancer has metastasized, the strategy shifts fundamentally. Because cancer cells are now in multiple locations, treatment must reach the entire body. This means systemic therapies, such as chemotherapy, immunotherapy, or targeted drugs delivered through the bloodstream, become the primary approach. Local treatments like surgery or radiation may still be used, but their role changes. Rather than aiming for a cure, they’re often employed to shrink a specific tumor that’s causing pain, pressing on a nerve, or blocking an organ.
The treatment goal itself often shifts from curative to palliative, meaning the focus becomes controlling the cancer’s growth, managing symptoms, and extending life rather than eliminating the disease entirely. This doesn’t mean treatment is less aggressive or that outcomes are predetermined. Many people with metastatic cancer respond well to systemic therapy and live for years. But the distinction between curable and manageable disease is one of the most important factors shaping a treatment plan.